[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100522872":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":11,"locations":23,"responsibleParty":37,"collaborators":11,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":11,"eligibilityCriteria":45,"healthyVolunteers":46,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":11,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":11,"overallStatus":59,"whyStopped":11,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Administration of BMS-986322","EXPERIMENTAL",null,[13],"Drug: BMS-986322",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","BMS-986322","Specified dose on specified days.",[9],[21],{"name":5,"affiliation":5,"role":22},"STUDY_DIRECTOR",[24],{"facility":25,"status":11,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":11},"Fortrea Clinical Research Unit","Madison","Wisconsin","53704","United States","US",{"type":32,"coordinates":33},"Point",[34,35],-89.40123,43.07305,{"lat":35,"lon":34},{"type":38,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100522872","phase-1-a-study-to-evaluate-the-drug-levels-metabolism-and-removal-of-bms-986322-in-healthy-adult-male-participants-100522872",false,"NCT06088264","A Study to Evaluate the Drug Levels, Metabolism, and Removal of BMS-986322 in Healthy Adult Male Participants","A Phase 1, Single-center, Open-label Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of [14C] BMS-986322 in Healthy Adult Male Participants","Inclusion Criteria:\n\n* Participants must have a body mass index of 18.0 to 32.0 kg\u002Fm2, inclusive.\n* Participants will be required to always use a latex or other synthetic condom with spermicide during any sexual activity\n* Participants must refrain from donating sperm during the entire study and for at least 90 days from dose of study drug.\n\nExclusion Criteria:\n\n* Participant must not have had any clinically significant diagnostic or therapeutic radiation exposure within the previous 12 months prior to admission to the clinic.\n* Participant must not be currently employed in a job requiring radiation exposure monitoring.\n* Participant must not have had any major surgery within 4 weeks of study drug administration that could impact upon the absorption of study drug",true,"MALE","18 Years","55 Years",{"count":51,"type":52},8,"ACTUAL","INTERVENTIONAL",[55],"PHASE1","The purpose of this study is to evaluate the drug levels, metabolism, and removal of BMS-986322 in healthy adult male participants.",[58],"Healthy Male Participants","COMPLETED","2024-03-28",{"date":62,"type":52},"2024-03-29",{"date":64,"type":52},"2023-10-31",{"date":66,"type":52},"2023-12-22",{"name":5,"class":6},1]